Von Lilienfeld-Toal M, Wagener J, Einsele H, et al. Invasive fungal infection. Dtsch Arztebl Int. 2019;116(16):271–8. https://doi.org/10.3238/arztebl.2019.0271.

Google Scholar 

Lass-Flörl C, Steixner S. The changing epidemiology of fungal infections. Mol Aspects Med. 2023;94:101215. https://doi.org/10.1016/j.mam.2023.101215.

Article  PubMed  CAS  Google Scholar 

Fang W, Wu J, Cheng M, et al. Diagnosis of invasive fungal infections: challenges and recent developments. J Biomed Sci. 2023;30(1):42. https://doi.org/10.1186/s12929-023-00926-2.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Sprute R, Nacov JA, Neofytos D, et al. Antifungal prophylaxis and pre-emptive therapy: when and how? Mol Aspects Med. 2023;92: 101190. https://doi.org/10.1016/j.mam.2023.101190.

Article  PubMed  CAS  Google Scholar 

Vitiello A, Ferrara F, Boccellino M, et al. Antifungal drug resistance: an emergent health threat. Biomedicines. 2023;11(4):1063. https://doi.org/10.3390/biomedicines11041063.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wu S, Song R, Liu T, et al. Antifungal therapy: novel drug delivery strategies driven by new targets. Adv Drug Deliv Rev. 2023;199:114967. https://doi.org/10.1016/j.addr.2023.114967.

Article  PubMed  CAS  Google Scholar 

Soldi LR, Coelho YNB, Paranhos LR, et al. The impact of antifungal prophylaxis in patients diagnosed with acute leukemias undergoing induction chemotherapy: a systematic review and meta-analysis. Clin Exp Med. 2023;23(7):3231–49. https://doi.org/10.1007/s10238-023-01062-9.

Article  PubMed  CAS  Google Scholar 

Carmo A, Rocha M, Pereirinha P, et al. Antifungals: from pharmacokinetics to clinical practice. Antibiotics (Basel). 2023;12(5):884. https://doi.org/10.3390/antibiotics12050884.

Article  PubMed  CAS  Google Scholar 

Chen L, Krekels EHJ, Verweij PE, et al. Pharmacokinetics and pharmacodynamics of posaconazole. Drugs. 2020;80(7):671–95. https://doi.org/10.1007/s40265-020-01306-y.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Chen L, Krekels EHJ, Heijnen AR, et al. An integrated population pharmacokinetic analysis for posaconazole oral suspension, delayed-release tablet, and intravenous infusion in healthy volunteers. Drugs. 2023;83(1):75–86. https://doi.org/10.1007/s40265-022-01819-8.

Article  PubMed  CAS  Google Scholar 

Stemler J, Mellinghoff SC, Khodamoradi Y, et al. Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). J Antimicrob Chemother. 2023;78(8):1813–26. https://doi.org/10.1093/jac/dkad143.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wong TY, Loo YS, Veettil SK, et al. Efficacy and safety of posaconazole for the prevention of invasive fungal infections in immunocompromised patients: a systematic review with meta-analysis and trial sequential analysis. Sci Rep. 2020;10(1):14575. https://doi.org/10.1038/s41598-020-71571-0.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Maertens JA, Girmenia C, Brüggemann RJ, et al. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. J Antimicrob Chemother. 2018;73(12):3221–30. https://doi.org/10.1093/jac/dky286.

PubMed  CAS  Google Scholar 

Van Daele R, Spriet I, Maertens J. Posaconazole in prophylaxis and treatment of invasive fungal infections: a pharmacokinetic, pharmacodyn amic and clinical evaluation. Expert Opin Drug Metab Toxicol. 2020;16(7):539–50. https://doi.org/10.1080/17425255.2020.1764939.

Article  PubMed  Google Scholar 

Dolton MJ, Ray JE, Chen SC, et al. Multicenter study of posaconazole therapeutic drug monitoring: exposure–response relationship and factors affecting concentration. Antimicrob Agents Chemother. 2012;56(11):5503–10. https://doi.org/10.1128/AAC.00802-12.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kably B, Launay M, Derobertmasure A, et al. Antifungal drugs TDM: trends and update. Ther Drug Monit. 2022;44(1):166–97. https://doi.org/10.1097/FTD.0000000000000952.

Article  PubMed  Google Scholar 

McCreary EK, Davis MR, Narayanan N, et al. Utility of triazole antifungal therapeutic drug monitoring: Insights from the Society of Infectious Diseases Pharmacists: endorsed by the Mycoses Study Group Education and Research Consortium. Pharmacotherapy. 2023;43(10):1043–50. https://doi.org/10.1002/phar.2850.

Article  PubMed  CAS  Google Scholar 

Gómez-López A. Antifungal therapeutic drug monitoring: focus on drugs without a clear recommendation. Clin Microbiol Infect. 2020;26(11):1481–7. https://doi.org/10.1016/j.cmi.2020.05.037.

Article  PubMed  Google Scholar 

Chen L, Wang Y, Zhang T, et al. Utility of posaconazole therapeutic drug monitoring and assessment of plasma concentration threshold for effective prophylaxis of invasive fungal infections: a meta-analysis with trial sequential analysis. BMC Infect Dis. 2018;18(1):155. https://doi.org/10.1186/s12879-018-3055-3.

Article  PubMed  PubMed Central  Google Scholar 

Jia MM, Zhang QW, Qin ZF, et al. Deciphering the relationship between the trough concentration of posaconazole and its efficacy and safety in Chinese patients with hematological disorders. Front Pharmacol. 2020;11:575463. https://doi.org/10.3389/fphar.2020.575463.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Li W, Xia F, Zhou H, et al. Efficacy of posaconazole prophylaxis for fungal disease in hematology patients treated with chemotherapy and transplantation: an open-label, prospective, observational study. Front Microbiol. 2020;11:349. https://doi.org/10.3389/fmicb.2020.00349.

Article  PubMed  PubMed Central  Google Scholar 

Chen L, Krekels EHJ, Dong Y, et al. Meta-pharmacokinetic analysis of posaconazole following dosing of oral suspension, delayed-release tablet, and intravenous infusion in patients vs. healthy volunteers: Impact of clinical characteristics and race. Int J Antimicrob Agents. 2023;62(6):106995. https://doi.org/10.1016/j.ijantimicag.2023.106995.

Article  PubMed  CAS  Google Scholar 

Donnelly JP, Chen SC, Kauffman CA, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2020;71(6):1367–76. https://doi.org/10.1093/cid/ciz1008.

Article  PubMed  Google Scholar 

National Institute of Diabetes and Digestive and Kidney Diseases. Adverse Drug Reaction Probability Scale (Naranjo) in Drug Induced Liver Injury. LiverTox: Clinical and Research Information on Drug-Induced Liver [Internet]. [Updated 2019 May 4]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK548069/

Kraljevic M, Khanna N, Medinger M, et al. Clinical considerations on posaconazole administration and therapeutic drug monitoring in allogeneic hematopoietic cell transplant recipients. Med Mycol. 2021;59(7):701–11. https://doi.org/10.1093/mmy/myaa106.

Article  PubMed  CAS  Google Scholar 

Reynolds G, Urbancic KF, Fong CY, et al. Invasive fungal infection following venetoclax and posaconazole co-administration. Br J Haematol. 2023;203(4):593–8. https://doi.org/10.1111/bjh.19116.

Article  PubMed  CAS  Google Scholar 

Suh HJ, Yoon SH, Yu KS, et al. The genetic polymorphism UGT1A4*3 is associated with low posaconazole plasma concentrations in hematological malignancy patients receiving the oral suspension. Antimicrob Agents Chemother. 2018;62(7):e02230–e2317. https://doi.org/10.1128/AAC.02230-17.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Cojutti PG, Candoni A, Lazzarotto D, et al. Co-administration of proton pump inhibitors and/or of steroids may be a risk factor for low trough concentrations of posaconazole delayed-released tablets in adult patients with haematological malignancies. Br J Clin Pharmacol. 2018;84(11):2544–50. https://doi.org/10.1111/bcp.13707.

Article  PubMed  PubMed Central  CAS